Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175405 | 0.93 | AR (0.48) | ARKDM4ELMNAPOLBCYP3A4 | |
| SCHEMBL4180793 | 0.90 | AR (0.48) | ARKDM4ELMNAGAAMAPT | |
| SCHEMBL13909250 | 0.90 | AR (0.48) | ARKDM4ELMNAGAAMAPT | |
| SCHEMBL4168220 | 0.90 | AR (0.50) | ARKDM4ELMNAPOLBCYP3A4 | |
| SCHEMBL13909246 | 0.90 | AR (0.50) | ARKDM4ELMNAPOLBCYP3A4 | |
| SCHEMBL4174415 | 0.89 | AR (0.46) | ARLMNAGAA | |
| SCHEMBL13909422 | 0.89 | AR (0.46) | ARLMNAGAA | |
| SCHEMBL4184263 | 0.89 | AR (0.46) | ARLMNAGAA | |
| SCHEMBL4177582 | 0.89 | AR (0.45) | ARLMNAGAA | |
| SCHEMBL4170977 | 0.88 | MGLL (0.46) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | AR 145/4885ADORA3 2139/4885KDM4E 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.